NASDAQ:PTGX - Protagonist Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.39 +0.23 (+3.21 %) (As of 02/21/2019 03:24 PM ET)Previous Close$7.16Today's Range$7.08 - $7.4752-Week Range$5.49 - $23.97Volume57,236 shsAverage Volume108,637 shsMarket Capitalization$178.76 millionP/E Ratio-3.54Dividend YieldN/ABeta2.1 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California. Receive PTGX News and Ratings via Email Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTGX Previous Symbol CUSIPN/A Webwww.protagonist-inc.com Phone510-474-0170Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12Price-To-Earnings Trailing P/E Ratio-3.54 Forward P/E Ratio-4.68 P/E GrowthN/A Sales & Book Value Annual Sales$20.06 million Price / Sales8.91 Cash FlowN/A Price / Cash FlowN/A Book Value$5.89 per share Price / Book1.25Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-36,950,000.00 Net Margins-70.54% Return on Equity-24.08% Return on Assets-18.76%Miscellaneous Employees55 Outstanding Shares24,190,000Market Cap$178.76 million OptionableNot Optionable Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics Inc (NASDAQ:PTGX) posted its quarterly earnings data on Tuesday, November, 6th. The company reported ($0.38) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.01. The company earned $6.12 million during the quarter, compared to analyst estimates of $6.35 million. Protagonist Therapeutics had a negative net margin of 70.54% and a negative return on equity of 24.08%. View Protagonist Therapeutics' Earnings History. When is Protagonist Therapeutics' next earnings date? Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 6th 2019. View Earnings Estimates for Protagonist Therapeutics. What price target have analysts set for PTGX? 5 brokers have issued 1 year price objectives for Protagonist Therapeutics' shares. Their forecasts range from $13.00 to $21.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $16.25 in the next year. This suggests a possible upside of 120.2% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics. What is the consensus analysts' recommendation for Protagonist Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics. Has Protagonist Therapeutics been receiving favorable news coverage? News headlines about PTGX stock have trended positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Protagonist Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Are investors shorting Protagonist Therapeutics? Protagonist Therapeutics saw a decrease in short interest in the month of January. As of January 15th, there was short interest totalling 380,582 shares, a decrease of 26.8% from the December 31st total of 519,627 shares. Based on an average daily volume of 124,933 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.3% of the company's stock are sold short. View Protagonist Therapeutics' Current Options Chain. Who are some of Protagonist Therapeutics' key competitors? Some companies that are related to Protagonist Therapeutics include Arvinas (ARVN), Evolus (EOLS), Dynavax Technologies (DVAX), Dicerna Pharmaceuticals (DRNA), Vectura Group (VEGPF), Revance Therapeutics (RVNC), Cara Therapeutics (CARA), Eagle Pharmaceuticals (EGRX), Rocket Pharmaceuticals (RCKT), Viking Therapeutics (VKTX), CymaBay Therapeutics (CBAY), Basilea Pharmaceutica (BPMUF), Ra Pharmaceuticals (RARX), Synthorx (THOR) and Crinetics Pharmaceuticals (CRNX). What other stocks do shareholders of Protagonist Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Energy Transfer LP Unit (ET), Synergy Pharmaceuticals (SGYP), Bausch Health Companies (BHC), Ocular Therapeutix (OCUL), Verastem (VSTM), Viking Therapeutics (VKTX), Fate Therapeutics (FATE), CBL & Associates Properties (CBL), Strongbridge Biopharma (SBBP) and Omeros (OMER). Who are Protagonist Therapeutics' key executives? Protagonist Therapeutics' management team includes the folowing people: Dr. Dinesh V. Patel, CEO, Pres, Sec. & Director (Age 61)Dr. Richard S. Shames, Chief Medical Officer (Age 58)Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 68)Mr. Thomas P. O'Neil, Chief Financial Officer (Age 53)Dr. Mark Smythe, VP of Technology (Age 53) When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (5.65%), Great Point Partners LLC (3.95%), Millennium Management LLC (2.85%), Dimensional Fund Advisors LP (2.03%), BlackRock Inc. (1.08%) and Acadian Asset Management LLC (1.06%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics. Which major investors are selling Protagonist Therapeutics stock? PTGX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Alambic Investment Management L.P., Two Sigma Advisers LP, Algert Global LLC, Great Point Partners LLC, Tekla Capital Management LLC and Eqis Capital Management Inc.. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel and X LP Canaan. View Insider Buying and Selling for Protagonist Therapeutics. Which major investors are buying Protagonist Therapeutics stock? PTGX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Dimensional Fund Advisors LP, Fosun International Ltd, Barclays PLC, BlackRock Inc., Bank of America Corp DE, D. E. Shaw & Co. Inc. and Acadian Asset Management LLC. View Insider Buying and Selling for Protagonist Therapeutics. How do I buy shares of Protagonist Therapeutics? Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $7.38. How big of a company is Protagonist Therapeutics? Protagonist Therapeutics has a market capitalization of $178.52 million and generates $20.06 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Protagonist Therapeutics employs 55 workers across the globe. What is Protagonist Therapeutics' official website? The official website for Protagonist Therapeutics is http://www.protagonist-inc.com. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected] MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 131 (Vote Outperform)Underperform Votes: 192 (Vote Underperform)Total Votes: 323MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is the Difference Between Common Shares and Convertible Shares?